thalidomide has been researched along with Diplopia in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Diplopia: A visual symptom in which a single object is perceived by the visual cortex as two objects rather than one. Disorders associated with this condition include REFRACTIVE ERRORS; STRABISMUS; OCULOMOTOR NERVE DISEASES; TROCHLEAR NERVE DISEASES; ABDUCENS NERVE DISEASES; and diseases of the BRAIN STEM and OCCIPITAL LOBE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Plasmacytomas are monoclonal plasma cell tumors." | 1.42 | Diplopia and variable ptosis as the sole initial findings in a case of orbital plasmacytoma and multiple myeloma. ( Galea, M; McMillan, N; Weir, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galea, M | 1 |
| McMillan, N | 1 |
| Weir, C | 1 |
| Katodritou, E | 1 |
| Speletas, M | 1 |
| Pouli, A | 1 |
| Tsitouridis, J | 1 |
| Zervas, K | 1 |
| Terpos, E | 1 |
2 other studies available for thalidomide and Diplopia
| Article | Year |
|---|---|
Diplopia and variable ptosis as the sole initial findings in a case of orbital plasmacytoma and multiple myeloma.
Topics: Antineoplastic Agents, Alkylating; Biopsy; Blepharoptosis; Bone Marrow Cells; Cyclophosphamide; Dexa | 2015 |
Successful treatment of extramedullary plasmacytoma of the cavernous sinus using a combination of intermediate dose of thalidomide and dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cavernous Sinus; Dexamethas | 2007 |